Combining three markers of homologous recombination deficiency into a single score may improve treatment decisions for women with ovarian cancer, according to a study reported at the 2016 SGO Annual Meeting.
An ASCO expert panel has endorsed a Cancer Care Ontario guideline on the role of patient and disease factors in the selection of adjuvant therapy for women with early-stage breast cancer.
Ultrasound proved better than tomosynthesis at finding breast cancer in women with dense breasts where mammography had not detected any cancer.
Almost 29% of all cancer survivors in the United States have been burdened with financial issues as a result of their diagnosis and treatment.
Men who receive radiation therapy as treatment for their prostate cancer may have an increased risk of developing a secondary cancer, according to a meta-analysis of observational studies.
A panel of experts at the ASCO have reviewed and endorsed Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer.
ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.
Despite clinical trial evidence and recommendations that certain older breast cancer patients can forego radiation therapy after lumpectomy, most older patients continue to receive radiation therapy, according to a new study.
The FDA has approved the first single-dose intravenous NK1 receptor antagonist, fosaprepitant dimeglumine (Emend), for the treatment of nausea and vomiting that can accompany the use of moderately and highly emetogenic chemotherapy.
Nanoliposomal irinotecan combined with fluorouracil/leucovorin improved overall survival in metastatic pancreatic cancer patients who have already been treated with gemcitabine.